NCT04419025View on ClinicalTrials.gov

Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

September 23, 2020

Primary Completion Date

May 14, 2021

Study Completion Date

May 14, 2021

Conditions
COVIDSars-CoV2SARS-Associated Coronavirus as Cause of Disease Classified ElsewhereOxidative Stress
Interventions
DRUG

N-acetylcysteine

Oral formulation: 600 mg capsules of N-acetylcysteine

Trial Locations (4)

02138

CHA Cambridge Hospital, Cambridge

02149

CHA Everett Hospital, Everett

02143

CHA Respiratory Clinic, Somerville

02144

CHA Somerville campus, Somerville

All Listed Sponsors
lead

Cambridge Health Alliance

OTHER

NCT04419025 - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease | Biotech Hunter | Biotech Hunter